Quinn Opportunity Partners LLC Invests $1.29 Million in HealthEquity, Inc. (NASDAQ:HQY)

Quinn Opportunity Partners LLC acquired a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,470 shares of the company's stock, valued at approximately $1,292,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Arcadia Investment Management Corp MI bought a new stake in shares of HealthEquity in the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC boosted its stake in HealthEquity by 34.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after buying an additional 98 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in HealthEquity in the fourth quarter worth $39,000. UMB Bank n.a. boosted its stake in shares of HealthEquity by 65.6% during the fourth quarter. UMB Bank n.a. now owns 414 shares of the company's stock valued at $40,000 after purchasing an additional 164 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in HealthEquity by 1,934.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 468 shares of the company's stock worth $45,000 after acquiring an additional 445 shares during the last quarter. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

HealthEquity Price Performance

HQY stock traded up $1.75 during trading on Thursday, hitting $84.24. The stock had a trading volume of 416,587 shares, compared to its average volume of 760,856. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $115.59. The company's 50 day moving average price is $95.89 and its two-hundred day moving average price is $96.26. The stock has a market cap of $7.29 billion, a price-to-earnings ratio of 77.28, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20.

Insider Buying and Selling

In other HealthEquity news, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares in the company, valued at $4,433,820.30. This represents a 13.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total transaction of $446,487.50. Following the completion of the transaction, the director now directly owns 84,969 shares of the company's stock, valued at $6,597,842.85. This trade represents a 6.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 20,381 shares of company stock valued at $1,781,432. Company insiders own 2.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HQY. Wells Fargo & Company lifted their price objective on HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. KeyCorp decreased their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday. Barrington Research reiterated an "outperform" rating and issued a $112.00 price target on shares of HealthEquity in a research report on Friday, April 11th. Raymond James upgraded HealthEquity from an "outperform" rating to a "strong-buy" rating and cut their price objective for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Finally, The Goldman Sachs Group decreased their price objective on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research report on Thursday, March 27th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, HealthEquity presently has an average rating of "Buy" and a consensus price target of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.